The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I find it interesting you have made these comments now, a week after the final results. As you clearly like to make judgements, referring to UN decision and 'smugness', dare i suggest you are another with an agenda to promote negative sentiment?
Yes I have been around a long time, but only post if i think i have something useful to share / highlight. I am optimistic towards Starcom, the business is building nicely and the range of products is getting a wide coverage, part of which you have shown today. I am very much looking forward to what is coming next...
yrabsmurruc, 'I am sure the language subtly changed in the most recent update' Are you suggesting the company are being dishonest with their rns content? ------------------------------------ 'I suspect news is due soon, but how soon, others may know better than I...... does feel like what Mungo stated yesterday......3rd and 4th quarter before things pick up here, which for AIM is a small lifetime....so peeps will move on ...... for now....B' To clarify, you are saying that news is due soon but won't come until Q3 & Q4. Is that correct?
In the interim results for the 6 months ended 30 June 2017, released 29th September 2017; http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/STAR/13379645.html The Chairman commented, 'Loss after tax was $913,000 (H1 2016: $613,000). However, after adjusting for exchange rate differences, loss after tax was $693,000 (H1 2016: $561,000)'. Can any knowledgeable posters here (perhaps ShatAim), add further meaning to this statement and detail what they expect with regard 'exchange rate differences' in the audited financial results 2017 to be released this week?
If you weren't being manipulative, that's great. Everybody buys and sells including me, but that's not relevant here.
draft, you informed readers of this board a short while ago that you had sold out. Need I say more?